KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Finished Goods (2016)

AbbVie (ABBV) has disclosed Finished Goods for 5 consecutive years, with $556.0 million as the latest value for Q2 2016.

  • Quarterly Finished Goods rose 16.32% to $556.0 million in Q2 2016 from the year-ago period, while the trailing twelve-month figure was $556.0 million through Jun 2016, up 16.32% year-over-year, with the annual reading at $469.0 million for FY2015, 37.54% up from the prior year.
  • Finished Goods for Q2 2016 was $556.0 million at AbbVie, up from $552.0 million in the prior quarter.
  • The five-year high for Finished Goods was $640.0 million in Q3 2015, with the low at $280.0 million in Q3 2014.
  • Average Finished Goods over 5 years is $479.5 million, with a median of $485.0 million recorded in 2013.
  • The sharpest move saw Finished Goods tumbled 41.42% in 2014, then surged 128.57% in 2015.
  • Over 5 years, Finished Goods stood at $547.0 million in 2012, then fell by 11.33% to $485.0 million in 2013, then dropped by 29.69% to $341.0 million in 2014, then surged by 37.54% to $469.0 million in 2015, then increased by 18.55% to $556.0 million in 2016.
  • According to Business Quant data, Finished Goods over the past three periods came in at $556.0 million, $552.0 million, and $469.0 million for Q2 2016, Q1 2016, and Q4 2015 respectively.